What is the recommended diagnostic workup and management for vulvar carcinoma?

Vulvar Carcinoma: Diagnostic Workup and Management

For vulvar carcinoma, perform surgical staging with complete resection achieving 1-2 cm margins plus inguinofemoral lymph node assessment (either sentinel lymph node biopsy in select cases or lymphadenectomy), as lymph node status is the most critical determinant of survival. 1

Initial Diagnostic Workup

Clinical Evaluation

• Perform punch biopsy of all suspicious vulvar lesions, ensuring inclusion of underlying stroma while avoiding necrotic areas 2
• Document tumor size, location relative to vulvar midline (within or beyond 2 cm), relationship to adjacent structures (urethra, vagina, anus), and presence of multifocal disease 1
• Clinically palpate inguinofemoral lymph nodes, though recognize the high false-negative rate of clinical examination alone 2

Imaging Studies

• Consider chest x-ray initially; if abnormal, proceed to chest CT without contrast 1
• Consider pelvic MRI to aid in surgical and/or radiation treatment planning 1
• For T2 or larger tumors or when metastasis is suspected, obtain whole body PET/CT or chest/abdominal/pelvic CT 1

Surgical Staging and Primary Treatment

Staging System

• Use AJCC and FIGO staging systems, which involve complete surgical resection with at least 1-cm margins and inguinofemoral lymph node assessment 1

Primary Tumor Resection

• Perform radical local excision or modified radical vulvectomy through separate incisions from lymph node dissection (the historical en bloc approach caused excessive morbidity) 1
• Resect to the depth of the urogenital diaphragm for both radical local excision and radical vulvectomy 1
• Aim for 1-2 cm surgical margins at primary surgery 1

Lymph Node Management Based on Tumor Characteristics

Stage IA disease (<1 mm invasion):

• No lymphadenectomy required due to <1% risk of lymphatic metastases 1

Stage IB-II disease with tumor <4 cm, located ≥2 cm from vulvar midline, and clinically negative nodes:

• Perform unilateral inguinofemoral lymphadenectomy OR sentinel lymph node biopsy 1

Tumor located within 2 cm of or crossing vulvar midline:

• Perform bilateral inguinofemoral lymphadenectomy OR bilateral sentinel lymph node biopsy 1

Stage IB-II disease generally:

• Inguinal lymphadenectomy is recommended due to >8% risk of lymphatic metastases 1

Sentinel Lymph Node Biopsy Criteria

SLNB is appropriate ONLY when ALL of the following criteria are met:

• Unifocal tumor <4 cm 1, 3
• Clinically negative groin examination and imaging 1, 3
• No previous vulvar surgery that may have disrupted lymphatic flow 1, 3
• High-volume surgeon available with adequate surgical experience 1
• Use both radiocolloid (technetium-99m sulfur colloid) and dye for increased sensitivity 1

Intraoperative Management

• If unilateral lymphadenectomy reveals positive nodes, perform contralateral lymphadenectomy OR plan radiation to contralateral groin 1
• Evaluate grossly enlarged or suspicious nodes by frozen section intraoperatively to tailor extent and bilaterality of dissection 1

Management of Positive or Close Margins

Margins >0 mm but <8 mm (close margins):

• Consider re-resection OR adjuvant local radiation therapy, weighing risk-benefit ratio and morbidity 1
• Note: Evidence is lacking that re-resection or adjuvant radiation improves outcomes for close but negative margins 1

Positive margins involving urethra, anus, or vagina:

• Do NOT pursue re-resection if it would cause significant morbidity and adverse impact on quality of life 1

Positive margins in patients with inguinal node metastases:

• Re-resection may not be beneficial since these patients require EBRT ± chemotherapy regardless 1

Adjuvant Therapy

Node-positive disease:

• Administer postoperative radiation to the groin 3
• For negative margins but surgically positive inguinofemoral lymph nodes, give EBRT with concurrent chemotherapy 4
• For both positive margins AND positive nodes, give EBRT with brachytherapy, concurrent chemotherapy, and/or re-excision as appropriate 4

Locally advanced disease:

• Consider neoadjuvant radiation with concurrent platinum-based radiosensitizing chemotherapy 1
• If complete response not achieved, perform surgical resection of residual disease in appropriate surgical candidates 1

Chemotherapy regimens for concurrent use with radiation:

• Cisplatin, 5-FU plus cisplatin, or 5-FU plus mitomycin C 3

Recurrent/Metastatic Disease Management

Vulva-Confined Recurrence (No Prior Radiation)

Surgical pathway:

• Perform partial or total radical vulvectomy with unilateral or bilateral lymphadenectomy 4
• Consider pelvic exenteration for select central recurrences 4

Non-surgical pathway:

• EBRT, brachytherapy, and/or concurrent chemotherapy 4

Vulva-Confined Recurrence (Prior Radiation)

• Perform partial or total radical vulvectomy when feasible 4

Nodal or Distant Recurrence

Multiple pelvic nodes, distant metastases, or prior pelvic EBRT:

• Systemic therapy and/or selective EBRT (if feasible) OR palliative/best supportive care 4

Limited to inguinofemoral or pelvic lymph nodes:

• Consider resection of clinically enlarged and suspicious nodes 4
• If no prior radiation: EBRT with concurrent chemotherapy 4

Systemic Therapy Regimens

Preferred first-line regimens:

• Cisplatin/paclitaxel 4
• Carboplatin/paclitaxel 4
• Cisplatin/paclitaxel/bevacizumab 4

Other recommended regimens:

• Single-agent cisplatin or carboplatin 4

Second-line or subsequent treatment:

• Paclitaxel, erlotinib (category 2B), or cisplatin/gemcitabine (category 2B) 4

Prognosis for stage IVB disease:

• Distant lymph node involvement only: median survival 13.4 months 5
• Other distant metastases: median survival 6.01 months 5
• Combination chemotherapy plus radiation superior to radiation alone for both groups 5

Surveillance

Follow-up schedule:

• Every 3-6 months for 2 years, then every 6-12 months for years 3-5, then annually based on recurrence risk 1
• Cervical/vaginal cytology screening as indicated for lower genital tract neoplasia 1

Imaging for surveillance:

• For locally advanced and/or node-positive disease: optional chest/abdominal/pelvic CT every 6-12 months for 2-3 years 1
• Whole body PET/CT if recurrence/metastasis suspected 1

Patient education:

• Counsel on symptoms of potential recurrence, vulvar dystrophy, periodic self-examinations, lifestyle modifications, sexual health (including vaginal dilator use and lubricants), smoking cessation, and potential long-term treatment effects 1

Critical Prognostic Factors

Lymph node status is the single most important determinant of survival 1

Risk of contralateral metastases after negative unilateral lymphadenectomy is <3% 1

Depth of stromal invasion is measured from the epithelial-stromal junction of the adjacent most superficial dermal papilla to the deepest point of invasion 1